Table 5 Adverse events by body system and specific adverse events
| Â | Number of | Percent with | Â | Â | ||
|---|---|---|---|---|---|---|
Outcome | Trials | Patients | Ferric carboxymaltose | Control | RB or RR 95% CI | NNTp/H 95% CI |
Comparison with oral iron | ||||||
Body system and preferred term | ||||||
GI disorder | 5 | 1539 | 13 | 32 | 0.44 (0.36 to 0.54) | 5.4 (4.4 to 7.1) |
General, administrative site | 5 | 1539 | 11 | 4 | 2.8 (1.9 to 4.2) | 15 (11 to 24) |
Infection, infestation | 5 | 1539 | 14 | 12 | 1.2 (0.9 to 1.6) | not calculated |
Metabolism, nutrition, investigation | 4 | 1195 | 11 | 5 | 2.2 (1.4 to 3.4) | 17 (11 to 33) |
Nervous system | 5 | 1539 | 10 | 9 | 1.3 (0.9 to 1.7) | not calculated |
Specific adverse events | ||||||
Constipation | 4 | 1339 | 3 | 13 | 0.3 (0.2 to 0.4) | 9.8 (7.6 to 14) |
Diarrhoea | 3 | 906 | 2 | 5 | 0.5 (0.2 to 0.9) | 33 (18 to 230) |
Nausea/vomiting | 3 | 906 | 3 | 10 | 0.4 (0.2 to 0.6) | 14 (9.5 to 27) |
Headache | 5 | 1539 | 7 | 7 | 1.2 (0.8 to 1.7) | not calculated |
Comparison with IV saline | ||||||
Body system and preferred term | ||||||
GI disorder | 2 | 1577 | 8 | 5 | 1.6 (1.1 to 2.4) | 34 (19 to 210) |
General, administrative site | 2 | 1577 | 6 | 2 | 2.5 (1.5 to 4.3) | 25 (17 to 49) |
Infection, infestation | 2 | 1577 | 9 | 6 | 1.1 (0.8 to 1.6) | not calculated |
Nervous system | 2 | 1577 | 8 | 6 | 1.2 (0.9 to 1.8) | not calculated |
Respiratory system | 2 | 1577 | 2 | 2 | 0.8 (0.4 to 1.5) | not calculated |